



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

September 2020





© 2021 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8515  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

September 2020

N = 7251



Health Authority	Male	Female	All
FRASER	1409	417	1826
INTERIOR	408	102	510
NORTHERN	138	87	225
VANCOUVER COASTAL	3307	433	3740
VANCOUVER ISLAND	773	151	924
	<b>6035</b>	<b>1190</b>	<b>7225</b>
		<b>Unknown/not stated:</b>	<b>26</b>
		<b>Total:</b>	<b>7251</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (September 2015 - September 2020)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (September 2015 - September 2020)








### 1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (September 2015 - September 2020)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (September 2015 - September 2020)






### 1.6 Percent Distribution of Active Participants by CD4 Count (September 2015 - September 2020)






### 1.7 Percent Distribution of Inactive Participants by CD4 Count (September 2015 - September 2020)






### 1.8 Active and Inactive Participants (September 2015 - September 2020)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (September 2015 - September 2020)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (September 2015 - September 2020)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(September 2015 - September 2020)








### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (September 2015 - September 2020)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(September 2015 - September 2020)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (September 2015 - September 2020)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(September 2015 - September 2020)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (September 2015 - September 2020)





1.17 Distribution of Participants on Entry/Integrase Inhibitors  
at the time of first start of ARV Therapy by INGREDIENT  
(September 2015 - September 2020)






1.18 Baseline CD4 for Antiretroviral First Starts  
(September 2015 - September 2020)






### 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (September 2015 - September 2020)








### 1.20 Cumulative Resistance Testing Results by Resistance Category (September 2015 - September 2020)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (September 2015 - September 2020)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	28	5	0	5	1	820	5	<40	3
1988	29	5	0	5	3	400	5	<40	3
1989	27	52	1	53	30	465	50	<40	3
1990	26	53	1	54	29	500	47	<40	3
1991	26	37	3	40	21	650	36	<40	3
1992	26	59	5	64	26	585	50	<40	3
1993	25	126	15	141	100	580	130	<40	3
1994	24	80	13	93	60	535	85	<40	3
1995	24	133	19	152	106	565	134	<40	3
1996	22	325	46	371	233	600	328	<40	3
1997	20	262	32	294	194	630	255	<40	3
1998	19	192	43	235	145	570	202	<40	3
1999	19	158	36	194	124	540	170	<40	3
2000	19	120	31	151	102	579	131	<40	3
2001	19	110	26	136	82	570	116	<40	3
2002	18	117	23	140	92	576	122	<40	3
2003	17	142	29	171	101	600	149	<40	3
2004	16	151	35	186	122	605	158	<40	3
2005	15	180	43	223	149	630	189	<40	3
2006	14	181	34	215	127	620	179	<40	3
2007	13	240	44	284	180	625	238	<40	3
2008	12	269	64	333	213	670	280	<40	3
2009	11	296	62	358	223	640	301	<40	3
2010	10	264	66	330	214	685	273	<40	3
2011	9	317	64	381	247	680	322	<40	3
2012	8	263	59	322	197	720	264	<40	3
2013	7	260	64	324	199	680	263	<40	3
2014	6	275	49	324	203	672	270	<40	3
2015	5	278	46	324	212	700	276	<40	3
2016	4	257	54	311	188	680	252	<40	3
2017	3	211	35	246	173	670	213	<40	3
2018	2	201	53	254	170	680	220	<40	3

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
2019	1	235	50	285	209	650	254	<40	3
2020	0	162	47	209	166	595	192	<40	3
<b>Total:</b>		<b>6016</b>	<b>1192</b>	<b>7208</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	7393	787	2456	<40	2146	610
FEB-2019	7368	793	1854	<40	1583	620
MAR-2019	7407	790	2085	<40	1753	610
APR-2019	7358	796	2141	<40	1746	610
MAY-2019	7416	791	2127	<40	1766	620
JUN-2019	7358	803	1926	<40	1593	620
JUL-2019	7370	810	2111	<40	1695	620
AUG-2019	7366	807	2106	<40	1622	602
SEP-2019	7338	805	2011	<40	1568	600
OCT-2019	7389	781	2140	<40	1746	620
NOV-2019	7342	779	2026	<40	1580	630
DEC-2019	7342	777	1700	<40	1296	610
JAN-2020	7357	774	2227	<40	1718	610
FEB-2020	7330	776	1882	<40	1413	623
MAR-2020	7387	768	1628	<40	1202	620
APR-2020	7408	770	767	<40	571	600
MAY-2020	7400	776	1186	<40	881	600
JUN-2020	7377	783	1558	<40	1127	620
JUL-2020	7348	793	1918	<40	1405	610
AUG-2020	7274	791	1848	<40	1282	630
SEP-2020	7251	784	1735	<40	1155	620

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	627	193	73	73	65	350
FEB-2019	658	156	75	108	66	590
MAR-2019	628	168	73	729	60	400
APR-2019	671	157	81	<50	71	480
MAY-2019	616	201	77	91	69	440
JUN-2019	679	160	78	<40	71	510
JUL-2019	667	162	70	<40	58	525
AUG-2019	686	167	80	50	67	510
SEP-2019	716	152	96	<40	81	580
OCT-2019	658	193	81	102	69	470
NOV-2019	679	179	68	<40	58	560
DEC-2019	666	180	57	<40	49	480
JAN-2020	641	191	71	255	47	460
FEB-2020	681	178	72	<40	59	480
MAR-2020	639	195	54	<40	37	470
APR-2020	618	209	28	116	22	555
MAY-2020	635	200	43	<40	31	490
JUN-2020	666	186	58	<40	47	480
JUL-2020	732	164	73	<40	57	620
AUG-2020	821	145	77	<40	65	480
SEP-2020	876	141	97	<40	69	610

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2019	7364	627	14	20	191	159	35	13564
FEB-2019	7346	658	7	16	160	181	-18	13593
MAR-2019	7367	628	15	13	187	149	21	13613
APR-2019	7324	671	10	15	152	182	-43	13641
MAY-2019	7389	616	11	21	197	136	65	13683
JUN-2019	7329	679	14	13	136	191	-60	13704
JUL-2019	7343	667	13	13	181	164	14	13727
AUG-2019	7338	686	12	18	170	174	-5	13763
SEP-2019	7310	716	14	15	181	204	-28	13790
OCT-2019	7323	658	3	13	223	150	13	13819
NOV-2019	7316	679	9	17	165	170	-7	13852
DEC-2019	7311	666	8	12	164	157	-5	13879
JAN-2020	7329	641	10	12	183	155	18	13902
FEB-2020	7296	681	12	19	141	172	-33	13938
MAR-2020	7358	639	14	23	210	153	62	13974
APR-2020	7382	618	12	8	158	127	24	13999
MAY-2020	7377	635	10	15	130	133	-5	14024
JUN-2020	7350	666	8	9	126	149	-27	14041
JUL-2020	7316	732	15	12	160	187	-34	14073
AUG-2020	7236	821	18	11	170	240	-80	14093
SEP-2020	7208	876	18	8	228	242	-28	14113

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2019	55	6800	485	53	<b>7393</b>	0.74%	91.98%	6.56%	0.72%	<b>100.00%</b>
FEB-2019	54	6775	490	49	<b>7368</b>	0.73%	91.95%	6.65%	0.67%	<b>100.00%</b>
MAR-2019	60	6808	489	50	<b>7407</b>	0.81%	91.91%	6.60%	0.68%	<b>100.00%</b>
APR-2019	57	6764	489	48	<b>7358</b>	0.77%	91.93%	6.65%	0.65%	<b>100.00%</b>
MAY-2019	56	6824	491	45	<b>7416</b>	0.76%	92.02%	6.62%	0.61%	<b>100.00%</b>
JUN-2019	58	6771	481	48	<b>7358</b>	0.79%	92.02%	6.54%	0.65%	<b>100.00%</b>
JUL-2019	61	6772	489	48	<b>7370</b>	0.83%	91.89%	6.64%	0.65%	<b>100.00%</b>
AUG-2019	60	6775	481	50	<b>7366</b>	0.81%	91.98%	6.53%	0.68%	<b>100.00%</b>
SEP-2019	57	6744	486	51	<b>7338</b>	0.78%	91.91%	6.62%	0.70%	<b>100.00%</b>
OCT-2019	61	6788	488	52	<b>7389</b>	0.83%	91.87%	6.60%	0.70%	<b>100.00%</b>
NOV-2019	60	6746	486	50	<b>7342</b>	0.82%	91.88%	6.62%	0.68%	<b>100.00%</b>
DEC-2019	61	6755	478	48	<b>7342</b>	0.83%	92.00%	6.51%	0.65%	<b>100.00%</b>
JAN-2020	60	6757	484	56	<b>7357</b>	0.82%	91.84%	6.58%	0.76%	<b>100.00%</b>
FEB-2020	59	6736	476	59	<b>7330</b>	0.80%	91.90%	6.49%	0.80%	<b>100.00%</b>
MAR-2020	60	6790	486	51	<b>7387</b>	0.81%	91.92%	6.58%	0.69%	<b>100.00%</b>
APR-2020	61	6814	483	50	<b>7408</b>	0.82%	91.98%	6.52%	0.67%	<b>100.00%</b>
MAY-2020	60	6809	481	50	<b>7400</b>	0.81%	92.01%	6.50%	0.68%	<b>100.00%</b>
JUN-2020	59	6782	485	51	<b>7377</b>	0.80%	91.93%	6.57%	0.69%	<b>100.00%</b>
JUL-2020	61	6767	472	48	<b>7348</b>	0.83%	92.09%	6.42%	0.65%	<b>100.00%</b>
AUG-2020	70	6696	457	51	<b>7274</b>	0.96%	92.05%	6.28%	0.70%	<b>100.00%</b>
SEP-2020	83	6657	458	53	<b>7251</b>	1.14%	91.81%	6.32%	0.73%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)









**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)**

	emtricitabine			
	Initial		All	
JAN-2019	27	77%	3697	51%
FEB-2019	16	55%	3674	51%
MAR-2019	14	70%	3702	51%
APR-2019	16	57%	3662	51%
MAY-2019	27	66%	3689	51%
JUN-2019	18	86%	3643	51%
JUL-2019	14	64%	3650	51%
AUG-2019	22	61%	3626	51%
SEP-2019	22	81%	3622	51%
OCT-2019	24	86%	3663	51%
NOV-2019	25	76%	3671	51%
DEC-2019	26	96%	3713	52%
JAN-2020	21	91%	3762	52%
FEB-2020	33	92%	3781	53%
MAR-2020	30	83%	3855	54%
APR-2020	19	76%	3888	54%
MAY-2020	23	96%	3916	54%
JUN-2020	12	71%	3928	55%
JUL-2020	26	81%	3950	55%
AUG-2020	17	85%	3926	55%
SEP-2020	18	90%	3941	56%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS







**2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)**

	tipranavir			
	Initial		All	
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%
AUG-2019	0	0%	1	0%
SEP-2019	0	0%	1	0%
OCT-2019	0	0%	1	0%
NOV-2019	0	0%	1	0%
DEC-2019	0	0%	1	0%
JAN-2020	0	0%	1	0%
FEB-2020	0	0%	1	0%
MAR-2020	0	0%	1	0%
APR-2020	0	0%	1	0%
MAY-2020	0	0%	0	0%
JUN-2020	0	0%	1	0%
JUL-2020	0	0%	1	0%
AUG-2020	0	0%	1	0%
SEP-2020	0	0%	1	0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	0 0%	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	0 0%	0 0%	2 67%	667 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	0 0%	0 0%	3 75%	660 35%	0 0%	223 12%	1 25%	680 36%	0 0%	322 17%
APR-2019	0 0%	0 0%	4 100%	645 35%	0 0%	222 12%	0 0%	677 36%	0 0%	320 17%
MAY-2019	0 0%	0 0%	5 100%	647 35%	0 0%	217 12%	0 0%	672 36%	0 0%	322 17%
JUN-2019	0 0%	0 0%	3 75%	633 35%	0 0%	211 12%	0 0%	664 36%	1 25%	320 18%
JUL-2019	0 0%	1 0%	2 100%	633 35%	0 0%	209 11%	0 0%	657 36%	0 0%	322 18%
AUG-2019	0 0%	1 0%	2 100%	624 35%	0 0%	205 11%	0 0%	647 36%	0 0%	324 18%
SEP-2019	0 0%	1 0%	4 80%	607 34%	0 0%	207 12%	0 0%	622 35%	1 20%	324 18%
OCT-2019	0 0%	1 0%	6 60%	608 35%	1 10%	209 12%	2 20%	596 34%	1 10%	330 19%
NOV-2019	0 0%	1 0%	5 71%	612 37%	0 0%	208 12%	1 14%	525 31%	1 14%	326 20%
DEC-2019	0 0%	1 0%	3 100%	607 37%	0 0%	203 12%	0 0%	513 31%	0 0%	324 20%
JAN-2020	0 0%	1 0%	2 100%	589 36%	0 0%	202 13%	0 0%	501 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	558 36%	0 0%	198 13%	0 0%	483 31%	0 0%	320 21%
MAR-2020	0 0%	1 0%	4 100%	547 36%	0 0%	195 13%	0 0%	464 31%	0 0%	315 21%
APR-2020	0 0%	1 0%	6 86%	542 36%	0 0%	190 13%	0 0%	456 30%	1 14%	313 21%
MAY-2020	0 0%	1 0%	1 50%	538 36%	0 0%	193 13%	0 0%	452 30%	1 50%	305 20%
JUN-2020	0 0%	1 0%	2 100%	526 36%	0 0%	189 13%	0 0%	448 30%	0 0%	307 21%
JUL-2020	0 0%	3 0%	2 50%	507 35%	0 0%	184 13%	2 50%	439 31%	0 0%	305 21%
AUG-2020	1 100%	4 0%	0 0%	502 36%	0 0%	179 13%	0 0%	423 30%	0 0%	294 21%
SEP-2020	0 0%	5 0%	1 33%	476 35%	0 0%	174 13%	0 0%	410 30%	2 67%	294 22%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	16 0%	15 75%	2429 63%	4 20%	729 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2431 63%	5 23%	726 19%	0 0%	40 1%	1 5%	651 17%
MAR-2019	0 0%	27 1%	8 62%	2479 64%	5 38%	745 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	8 57%	2493 64%	3 21%	736 19%	0 0%	36 1%	3 21%	636 16%
MAY-2019	0 0%	27 1%	19 68%	2554 64%	6 21%	746 19%	0 0%	37 1%	3 11%	634 16%
JUN-2019	0 0%	27 1%	10 77%	2556 65%	3 23%	743 19%	0 0%	37 1%	0 0%	624 16%
JUL-2019	0 0%	27 1%	13 81%	2603 65%	3 19%	755 19%	0 0%	38 1%	0 0%	628 16%
AUG-2019	0 0%	27 1%	24 86%	2647 65%	1 4%	755 19%	0 0%	36 1%	3 11%	625 15%
SEP-2019	0 0%	28 1%	7 47%	2648 65%	6 40%	757 19%	0 0%	37 1%	2 13%	627 15%
OCT-2019	0 0%	28 1%	13 87%	2717 66%	1 7%	758 18%	0 0%	34 1%	1 7%	628 15%
NOV-2019	3 13%	88 2%	16 70%	2741 65%	4 17%	770 18%	0 0%	33 1%	0 0%	621 15%
DEC-2019	12 63%	230 5%	6 32%	2716 64%	1 5%	744 18%	0 0%	33 1%	0 0%	606 14%
JAN-2020	9 50%	421 10%	7 39%	2687 62%	0 0%	707 16%	0 0%	32 1%	2 11%	594 14%
FEB-2020	14 52%	602 14%	11 41%	2644 60%	2 7%	654 15%	0 0%	29 1%	0 0%	576 13%
MAR-2020	19 68%	755 17%	7 25%	2624 58%	1 4%	623 14%	1 4%	30 1%	0 0%	562 12%
APR-2020	7 50%	827 18%	6 43%	2589 57%	1 7%	607 13%	0 0%	29 1%	0 0%	544 12%
MAY-2020	10 56%	911 20%	6 33%	2555 56%	2 11%	597 13%	0 0%	27 1%	0 0%	541 12%
JUN-2020	4 31%	1024 22%	9 69%	2538 55%	0 0%	583 13%	1 8%	28 1%	0 0%	538 12%
JUL-2020	9 38%	1142 24%	10 42%	2512 54%	5 21%	551 12%	0 0%	29 1%	0 0%	527 11%
AUG-2020	10 59%	1222 26%	6 35%	2463 52%	1 6%	518 11%	0 0%	29 1%	0 0%	521 11%
SEP-2020	13 93%	1341 28%	1 7%	2442 51%	0 0%	499 10%	0 0%	29 1%	0 0%	504 11%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2019	1830	24.75	1481	20.03	3061	41.40	100	1.35	53	0.72	868	11.74
FEB-2019	1802	24.46	1478	20.06	3072	41.69	99	1.34	49	0.67	868	11.78
MAR-2019	1794	24.22	1471	19.86	3124	42.18	98	1.32	50	0.68	870	11.75
APR-2019	1760	23.92	1458	19.82	3135	42.61	100	1.36	48	0.65	857	11.65
MAY-2019	1773	23.91	1448	19.53	3196	43.10	97	1.31	45	0.61	857	11.56
JUN-2019	1738	23.62	1438	19.54	3195	43.42	95	1.29	48	0.65	844	11.47
JUL-2019	1712	23.23	1427	19.36	3236	43.91	92	1.25	48	0.65	855	11.60
AUG-2019	1686	22.89	1402	19.03	3295	44.73	94	1.28	50	0.68	839	11.39
SEP-2019	1697	23.13	1361	18.55	3298	44.94	93	1.27	51	0.70	838	11.42
OCT-2019	1702	23.03	1339	18.12	3357	45.43	93	1.26	52	0.70	846	11.45
NOV-2019	1666	22.69	1272	17.32	3424	46.64	91	1.24	50	0.68	839	11.43
DEC-2019	1643	22.38	1248	17.00	3483	47.44	92	1.25	48	0.65	828	11.28
JAN-2020	1617	21.98	1209	16.43	3562	48.42	87	1.18	56	0.76	826	11.23
FEB-2020	1573	21.46	1154	15.74	3644	49.71	85	1.16	59	0.80	815	11.12
MAR-2020	1540	20.85	1134	15.35	3755	50.83	85	1.15	51	0.69	822	11.13
APR-2020	1522	20.55	1129	15.24	3807	51.39	85	1.15	50	0.67	815	11.00
MAY-2020	1512	20.43	1113	15.04	3831	51.77	83	1.12	50	0.68	811	10.96
JUN-2020	1460	19.79	1087	14.73	3884	52.65	83	1.13	51	0.69	812	11.01
JUL-2020	1427	19.42	1059	14.41	3941	53.63	79	1.08	48	0.65	794	10.81
AUG-2020	1383	19.01	1029	14.15	3952	54.33	78	1.07	51	0.70	781	10.74
SEP-2020	1345	18.55	982	13.54	4004	55.22	76	1.05	53	0.73	791	10.91

**Definitions:**

n is number of participants on the specified regimen class in the specified month  
 % is ratio of n and total number of participants on ART in the specified month





### 2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	2	4	340
MAY-2019	21	1	0	6	8	4	440
JUN-2019	13	2	1	1	2	5	430
JUL-2019	13	1	1	1	3	7	530
AUG-2019	18	0	1	6	4	6	390
SEP-2019	15	0	0	2	4	7	530
OCT-2019	13	1	1	4	4	3	380
NOV-2019	17	4	1	1	1	10	520
DEC-2019	12	0	2	4	2	4	350
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	23	4	0	3	1	10	550
APR-2020	8	0	0	3	0	5	686
MAY-2020	15	1	0	3	4	7	400
JUN-2020	9	1	0	3	4	1	380
JUL-2020	12	3	0	0	2	4	500
AUG-2020	11	3	1	3	2	1	225
SEP-2020	8	3	2	1	0	0	71

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start







**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2019	12252	3830
FEB-2019	12260	3829
MAR-2019	12290	3859
APR-2019	12316	3882
MAY-2019	12332	3883
JUN-2019	12332	3888
JUL-2019	12349	3903
AUG-2019	12381	3920
SEP-2019	12400	3938
OCT-2019	12434	3962
NOV-2019	12456	3971
DEC-2019	12480	3986
JAN-2020	12535	4032
FEB-2020	12566	4049
MAR-2020	12566	4039
APR-2020	12544	4015
MAY-2020	12533	4002
JUN-2020	12511	3980
JUL-2020	12488	3947
AUG-2020	12457	3924
SEP-2020	12421	3896

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved

**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
September 2020

N = 7251

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2020

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







### 3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2020

#### FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



#### SURREY BY POSTAL CODE







### 3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2020

#### VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



#### VANCOUVER BY POSTAL CODE







### 3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2020

#### VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



#### VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2020

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	*
	35-49	9	10	*
	50+	27	39	*
	<b>Total HSDA:</b>	<b>42</b>	<b>55</b>	<b>28</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>73</b>	<b>98</b>	<b>56</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>375</b>	<b>509</b>	<b>278</b>	
THOMPSON/CARIBOO/ SHUSWAP	20-34	18	18	10
	35-49	70	76	50
	50+	110	180	88
	<b>Total HSDA:</b>	<b>198</b>	<b>274</b>	<b>148</b>
<b>Total HA:</b>		<b>688</b>	<b>936</b>	<b>510</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>688</b>	<b>936</b>	<b>510</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	546	744	408
Female	142	192	102

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	510	55	630	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)







### 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	20	12
	5 years or more	10	5
	<5 years	12	11
	<b>Total HSDA:</b>	<b>42</b>	<b>28</b>
KOOTENAY BOUNDARY	10 years or more	47	34
	5 years or more	16	12
	<5 years	10	10
	<b>Total HSDA:</b>	<b>73</b>	<b>56</b>
OKANAGAN	10 years or more	231	160
	5 years or more	80	65
	<5 years	64	53
	<b>Total HSDA:</b>	<b>375</b>	<b>278</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	110	79
	5 years or more	43	37
	<5 years	45	32
	<b>Total HSDA:</b>	<b>198</b>	<b>148</b>
<b>Total HA:</b>		<b>688</b>	<b>510</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	408	285
	5 years or more	149	119
	<5 years	131	106
<b>Total HA:</b>		<b>688</b>	<b>510</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	46	64	15	25
KOOTENAY BOUNDARY	73	123	26	44
OKANAGAN	229	947	61	286
THOMPSON/CARIBOO/SHUSWAP	139	524	37	132
<b>Total:</b>	<b>487</b>	<b>1658</b>	<b>139</b>	<b>487</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
<b>Total:</b>	<b>90</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	31	33	24
	35-49	97	106	68
	50+	246	324	183
	<b>Total HSDA:</b>	<b>381</b>	<b>470</b>	<b>281</b>
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>1048</b>	<b>1415</b>	<b>763</b>
FRASER SOUTH	0-19	5	5	*
	20-34	112	114	*
	35-49	326	369	*
	50+	563	835	*
	<b>Total HSDA:</b>	<b>1006</b>	<b>1323</b>	<b>782</b>
<b>Total HA:</b>		<b>2435</b>	<b>3208</b>	<b>1826</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	16	16	11
	20-34	261	265	173
	35-49	757	836	562
	50+	1401	2091	1080
<b>Total HA:</b>		<b>2435</b>	<b>3208</b>	<b>1826</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1842	2453	1409
Female	593	755	417

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1826	52	630	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	231	170
	5 years or more	76	56
	<5 years	74	55
	<b>Total HSDA:</b>	<b>381</b>	<b>281</b>
FRASER NORTH	10 years or more	613	425
	5 years or more	245	193
	<5 years	190	145
	<b>Total HSDA:</b>	<b>1048</b>	<b>763</b>
FRASER SOUTH	10 years or more	585	443
	5 years or more	218	162
	<5 years	203	177
	<b>Total HSDA:</b>	<b>1006</b>	<b>782</b>
<b>Total HA:</b>		<b>2435</b>	<b>1826</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1429	1038
	5 years or more	539	411
	<5 years	467	377
<b>Total HA:</b>		<b>2435</b>	<b>1826</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	144	517	31	56
FRASER NORTH	254	1585	51	225
FRASER SOUTH	219	1600	47	486
<b>Total:</b>	<b>617</b>	<b>3702</b>	<b>129</b>	<b>767</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	187
FRASER NORTH	645
FRASER SOUTH	423
<b>Total:</b>	<b>1255</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>346</b>	<b>498</b>
RICHMOND	0-19	*	*	0
	20-34	*	*	24
	35-49	*	*	33
	50+	*	*	82
	<b>Total HSDA:</b>		<b>192</b>	<b>242</b>
VANCOUVER	0-19	15	15	8
	20-34	445	460	288
	35-49	1348	1509	938
	50+	2882	4964	2089
	<b>Total HSDA:</b>	<b>4690</b>	<b>6948</b>	<b>3323</b>
<b>Total HA:</b>		<b>5228</b>	<b>7688</b>	<b>3740</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	17	17	9
	20-34	506	522	332
	35-49	1475	1647	1027
	50+	3230	5502	2372
<b>Total HA:</b>		<b>5228</b>	<b>7688</b>	<b>3740</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4618	6749	3307
Female	608	937	433

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3740	54	650	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	197	153
	5 years or more	86	69
	<5 years	63	56
	<b>Total HSDA:</b>	<b>346</b>	<b>278</b>
RICHMOND	10 years or more	106	73
	5 years or more	40	28
	<5 years	46	38
	<b>Total HSDA:</b>	<b>192</b>	<b>139</b>
VANCOUVER	10 years or more	2914	1990
	5 years or more	1067	772
	<5 years	709	561
	<b>Total HSDA:</b>	<b>4690</b>	<b>3323</b>
<b>Total HA:</b>		<b>5228</b>	<b>3740</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3217	2216
	5 years or more	1193	869
	<5 years	818	655
<b>Total HA:</b>		<b>5228</b>	<b>3740</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	178	404	57	87
RICHMOND	43	291	10	89
VANCOUVER	627	10992	206	5209
<b>Total:</b>	<b>848</b>	<b>11687</b>	<b>273</b>	<b>5385</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	5
RICHMOND	5
VANCOUVER	74
<b>Total:</b>	<b>84</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA







**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>329</b>	<b>468</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>123</b>	<b>166</b>
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>753</b>	<b>1071</b>
<b>Total HA:</b>		<b>1205</b>	<b>1705</b>	<b>924</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>1205</b>	<b>1705</b>	<b>924</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	999	1408	773
Female	206	297	151

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	924	55	570	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	194	156
	5 years or more	70	57
	<5 years	65	49
	<b>Total HSDA:</b>	<b>329</b>	<b>262</b>
NORTH VANCOUVER ISLAND	10 years or more	72	61
	5 years or more	36	26
	<5 years	15	13
	<b>Total HSDA:</b>	<b>123</b>	<b>100</b>
SOUTH VANCOUVER ISLAND	10 years or more	442	308
	5 years or more	156	131
	<5 years	155	123
	<b>Total HSDA:</b>	<b>753</b>	<b>562</b>
<b>Total HA:</b>		<b>1205</b>	<b>924</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	708	525
	5 years or more	262	214
	<5 years	235	185
<b>Total HA:</b>		<b>1205</b>	<b>924</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	197	878	79	194
NORTH VANCOUVER ISLAND	149	268	48	75
SOUTH VANCOUVER ISLAND	215	1822	45	546
<b>Total:</b>	<b>561</b>	<b>2968</b>	<b>172</b>	<b>815</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	43
NORTH VANCOUVER ISLAND	42
SOUTH VANCOUVER ISLAND	116
<b>Total:</b>	<b>201</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	5	5	*
	35-49	17	20	*
	50+	21	27	*
	<b>Total HSDA:</b>	<b>43</b>	<b>52</b>	<b>27</b>
NORTH WEST	20-34	9	10	*
	35-49	19	34	*
	50+	40	65	*
	<b>Total HSDA:</b>	<b>68</b>	<b>109</b>	<b>51</b>
NORTHERN INTERIOR	0-19	5	5	*
	20-34	23	24	*
	35-49	65	83	*
	50+	96	163	*
	<b>Total HSDA:</b>	<b>189</b>	<b>275</b>	<b>147</b>
<b>Total HA:</b>		<b>300</b>	<b>436</b>	<b>225</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	37	39	*
	35-49	101	137	*
	50+	157	255	*
<b>Total HA:</b>		<b>300</b>	<b>436</b>	<b>225</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	183	269	138
Female	117	167	87

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	225	51	540	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	21	12
	5 years or more	14	8
	<5 years	8	7
	<b>Total HSDA:</b>	<b>43</b>	<b>27</b>
NORTH WEST	10 years or more	35	26
	5 years or more	21	16
	<5 years	12	9
	<b>Total HSDA:</b>	<b>68</b>	<b>51</b>
NORTHERN INTERIOR	10 years or more	80	63
	5 years or more	66	52
	<5 years	43	32
	<b>Total HSDA:</b>	<b>189</b>	<b>147</b>
<b>Total HA:</b>		<b>300</b>	<b>225</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	136	101
	5 years or more	101	76
	<5 years	63	48
<b>Total HA:</b>		<b>300</b>	<b>225</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	40	62	3	*
NORTH WEST	83	166	17	*
NORTHERN INTERIOR	117	459	20	*
<b>Total:</b>	<b>240</b>	<b>687</b>	<b>40</b>	<b>224</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	10
NORTH WEST	18
NORTHERN INTERIOR	10
<b>Total:</b>	<b>38</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





### 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	25	41	16
	THOMPSON/CARIBOO/SHUSWAP	25	48	21
	<b>Total HA:</b>	<b>62</b>	<b>108</b>	<b>48</b>
FRASER	FRASER EAST	37	47	26
	FRASER NORTH	52	89	42
	FRASER SOUTH	81	114	55
	<b>Total HA:</b>	<b>170</b>	<b>250</b>	<b>123</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	24	47	20
	RICHMOND	10	15	6
	VANCOUVER	479	871	374
	<b>Total HA:</b>	<b>513</b>	<b>933</b>	<b>400</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	81	38
	NORTH VANCOUVER ISLAND	19	28	17
	SOUTH VANCOUVER ISLAND	41	85	34
	<b>Total HA:</b>	<b>111</b>	<b>194</b>	<b>89</b>
NORTHERN	NORTH EAST	12	15	11
	NORTH WEST	27	58	22
	NORTHERN INTERIOR	74	114	65
	<b>Total HA:</b>	<b>113</b>	<b>187</b>	<b>98</b>
<b>Total:</b>		<b>969</b>	<b>1672</b>	<b>758</b>

**Total:**

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	612	1072	480
Female	357	600	278

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	758	52	500	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Bictegravir:** an INTEGRASE INHIBITOR from Gilead Sciences.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicistat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

**Complera (CPL):** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.







## Monthly Report

**Descovy (DSC):** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay, DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare.

**Doravirine:** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

**Efavirenz (Sustiva, Auro efavirenz, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine (FTC):** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intelence, ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya (GNV):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





## Monthly Report

**Maraviroc (Celsentri, MVC):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**Odefsey (ODF):** the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





## Monthly Report

**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix (PZC):** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant, RPV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq (TRQ):** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir (TRZ):** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada (TRU):** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





## Monthly Report

---

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

